The OncoColon Panel is designed to detect mutations within oncogenes and tumor suppressor genes frequently mutated in human colorectal cancers (CRC). Diagnostic, prognostic, and predictive biologic markers in this panel are important in personalizing cancer care. The result of this test may guide a patient to the appropriate chemotherapy or clinical trial. The OncoColon Panel is designed to target ~469 mutations in the following 8 critical colon cancer-related genes: AKT1, BRAF, KRAS, NRAS, PIK3CA, PTEN, SMAD4 and SRC. 1,2,3,4
To open a printable assay summary in a new window, click the link below.
- Rothberg JM, et al. An integrated semiconductor device enabling non-optical genome sequencing. Nature, 2011 Jul20; 475(7356):348-52
- Dancey JE, et al. The genetic basis for cancer treatment decisions. Cell, 2012 Feb 3; 148(3): 409-20. Review.